Phio Pharmaceuticals Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Phio Pharmaceuticals Corp. on April 27, 2022. The report details corporate governance changes, specifically the appointment of a new director and amendments to the Company's Bylaws.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and does not contain financial performance data.
Material Changes
- Board Expansion: The Board of Directors increased its size to eight members.
- New Appointment: Patricia A. Bradford, former Senior Vice President Global Human Resources at Unisys Corporation, was appointed to the Board effective April 27, 2022, to serve until the 2022 annual meeting of stockholders.
- Bylaw Amendment: The Company amended its Amended and Restated Bylaws to allow the Board to fix the number of directors solely by resolution. Previously, the Bylaws mandated a minimum of two and a maximum of seven directors.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding business operations. Regarding risks and contingencies, the Company noted that Ms. Bradford will enter into a standard indemnification agreement. Under this agreement, the Company may be required to indemnify her for expenses, including attorneys' fees, judgments, fines, and settlement amounts arising from her service on the Board. Ms. Bradford will receive standard compensation and equity awards available to non-employee directors.
Key Facts for Investor Verification
- Verify the total number of directors on the Board is now eight.
- Confirm the terms of the indemnification agreement and potential liability exposure for Ms. Bradford.
- Review the "Director Compensation" section of the definitive Proxy Statement filed on April 30, 2021, for details on Ms. Bradford's compensation package.
- Note that the Bylaw amendment removes the previous cap of seven directors, granting the Board flexibility to adjust its size.